The bile acid TGR5 membrane receptor: From basic research to clinical application

Digestive and Liver Disease

Volumn 46, Issue 4, 2014, Pages 302-312

  Duboc, Henri ^a,b,c,d   Taché, Yvette ^a,b   Hofmann, Alan F ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Bile acids; Diabetes; Inflammation; Motility; TGR5 receptor

Indexed keywords

BILE ACID; BILE ACID CONJUGATE; BILE ACID TGR5 MEMBRANE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BILE DUCT; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DIGESTIVE SYSTEM CANCER; ENZYME ACTIVATION; EUKARYOTIC CELL; GENE EXPRESSION; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINAL SECRETION; INTESTINE MOTILITY; INTRACELLULAR SIGNALING; IRRITABLE COLON; KNOCKOUT MOUSE; LIVER; LIVER DISEASE; METABOLIC DISORDER; NONHUMAN; PANCREAS DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW;

BILE ACIDS; DIABETES; INFLAMMATION; MOTILITY; TGR5 RECEPTOR;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GASTROINTESTINAL NEOPLASMS; HEPATIC ENCEPHALOPATHY; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MICE; OBESITY; PANCREATITIS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84895520482     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.10.021     Document Type: Review

References (93)

1. Chen X., Lou G., Meng Z., Huang W. TGR5: a novel target for weight maintenance and glucose metabolism. Experimental Diabetes Research 2011, 2011:853501.
2. Hov J.R., Keitel V., Schrumpf E., Häussinger D., Karlsen T.H. TGR5 sequence variation in primary sclerosing cholangitis. Digestive Diseases 2011, 29:78-84.
3. Pols T.W.H., Noriega L.G., Nomura M., Auwerx J., Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. Journal of Hepatology 2011, 54:1263-1272.
4. Zhong M. TGR5 as a therapeutic target for treating obesity. Current Topics in Medicinal Chemistry 2010, 10:386-396.
5. Wang H., Chen J., Hollister K., Sowers L.C., Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Molecular Cell 1999, 3:543-553.
6. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiological Reviews 2009, 89:147-191.
7. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., Gonzalez F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102:731-744.
8. Maruyama T., Miyamoto Y., Nakamura T., et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochemical and Biophysical Research Communications 2002, 298:714-719.
9. Kawamata Y., Fujii R., Hosoya M., et al. A G protein-coupled receptor responsive to bile acids. Journal of Biological Chemistry 2003, 278:9435-9440.
10. Vassileva G., Golovko A., Markowitz L., et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochemical Journal 2006, 398:423-430.
11. Müssig K., Staiger H., Machicao F., et al. Preliminary report: genetic variation within the GPBAR1 gene is not associated with metabolic traits in white subjects at an increased risk for type 2 diabetes mellitus. Metabolism - Clinical and Experimental 2009, 58:1809-1811.
12. Gene Symbol Report | HUGO Gene Nomenclature Committee. Available at. http://www.genenames.org/data/hgnc_data.php%3Fhgnc_id=19680.
13. Greve J.W., Gouma D.J., Buurman W.A. Bile acids inhibit endotoxin-induced release of tumor necrosis factor by monocytes: an in vitro study. Hepatology 1989, 10:454-458.
14. Calmus Y., Guechot J., Podevin P., Bonnefis M.T., Giboudeau J., Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology 1992, 16:719-723.
15. Hov J.R., Keitel V., Laerdahl J.K., et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS ONE 2010, 5:e12403.
16. Maruyama T., Tanaka K., Suzuki J., et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. Journal of Endocrinology 2006, 191:197-205.
17. Keitel V., Görg B., Bidmon H.J., et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 2010, 58:1794-1805.
18. Alemi F., Kwon E., Poole D.P., et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. Journal of Clinical Investigation 2013, 123:1513-1530.
19. Poole D.P., Godfrey C., Cattaruzza F., et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterology and Motility 2010, 22:814-825. e227-228.
20. Karlström L., Cassuto J., Jodal M., Lundgren O. The importance of the enteric nervous system for the bile-salt-induced secretion in the small intestine of the rat. Scandinavian Journal of Gastroenterology 1983, 18:117-123.
21. Karlström L., Cassuto J., Jodal M., Lundgren O. Involvement of the enteric nervous system in the intestinal secretion induced by sodium deoxycholate and sodium ricinoleate. Scandinavian Journal of Gastroenterology 1986, 21:331-340.
22. Keitel V., Reinehr R., Gatsios P., et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 2007, 45:695-704.
23. Keitel V., Ullmer C., Häussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biological Chemistry 2010, 391:785-789.
24. Keitel V., Häussinger D. TGR5 in the biliary tree. Digestive Diseases 2011, 29:45-47.
25. Keitel V., Donner M., Winandy S., Kubitz R., Häussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochemical and Biophysical Research Communications 2008, 372:78-84.
26. Sato H., Genet C., Strehle A., et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochemical and Biophysical Research Communications 2007, 362:793-798.
27. Pellicciari R., Gioiello A., Macchiarulo A., et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. Journal of Medicinal Chemistry 2009, 52:7958-7961.
28. Gioiello A., Rosatelli E., Nuti R., et al. Patented TGR5 modulators: a review (2006 - present). Expert Opinion on Therapeutic Patent 2012, 22(12):1399-1414.
29. Rizzo G., Passeri D., De Franco F., et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Molecular Pharmacology 2010, 78:617-630.
30. Budzik B.W., Evans K.A., Wisnoski D.D., et al. Synthesis and structure-activity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists. Bioorganic and Medicinal Chemistry Letters 2010, 20:1363-1367.
31. Evans K.A., Budzik B.W., Ross S.A., et al. Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. Journal of Medicinal Chemistry 2009, 52:7962-7965.
32. Herbert M.R., Siegel D.L., Staszewski L., et al. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorganic and Medicinal Chemistry Letters 2010, 20:5718-5721.
33. Cipriani S., Mencarelli A., Chini M.G., et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE 2011, 6:e25637.
34. Kumar D.P., Rajagopal S., Mahavadi S., et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochemical and Biophysical Research Communications 2012, 427:600-605.
35. Lavoie B., Balemba O.B., Godfrey C., et al. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. Journal of Physiology (London) 2010, 588(Pt 17):3295-3305.
36. Vassileva G., Hu W., Hoos L., et al. Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. Journal of Endocrinology 2010, 205:225-232.
37. Pols T.W.H., Nomura M., Harach T., et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metabolism 2011, 14:747-757.
38. Wang Y.-D., Chen W.-D., Yu D., Forman B.M., Huang W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology 2011, 54:1421-1432.
39. Ichikawa R., Takayama T., Yoneno K., et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology 2012, 136:153-162.
40. Keitel V., Häussinger D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clinics and Research in Hepatology and Gastroenterology 2012.
41. Keitel V., Kubitz R., Häussinger D. Endocrine and paracrine role of bile acids. World Journal of Gastroenterology 2008, 14:5620-5629.
42. Keitel V., Cupisti K., Ullmer C., Knoefel W.T., Kubitz R., Häussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009, 50:861-870.
43. Péan N., Doignon I., Garcin I., et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology 2013, 58(4):1451-1460.
44. Masyuk A.I., Huang B.Q., Radtke B.N., et al. Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. American Journal of Physiology - Gastrointestinal and Liver Physiology 2013, 304:G1013-G1024.
45. Li T., Holmstrom S.R., Kir S., et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Molecular Endocrinology 2011, 25:1066-1071.
46. Watanabe M., Houten S.M., Mataki C., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439:484-489.
47. Thomas C., Gioiello A., Noriega L., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism 2009, 10:167-177.
48. Pols T.W.H., Noriega L.G., Nomura M., Auwerx J., Schoonjans K. The bile acid membrane receptor TGR5: a valuable metabolic target. Digestive Diseases 2011, 29:37-44.
49. Porez G., Prawitt J., Gross B., Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. Journal of Lipid Research 2012, 53:1723-1737.
50. Werneburg N.W., Yoon J.-H., Higuchi H., Gores G.J. Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. American Journal of Physiology - Gastrointestinal and Liver Physiology 2003, 285:G31-G36.
51. Raimondi F., Santoro P., Barone M.V., et al. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. American Journal of Physiology - Gastrointestinal and Liver Physiology 2008, 294:G906-G913.
52. Marzioni M., Ueno Y., Glaser S., et al. Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver. Liver International 2007, 27:558-568.
53. Marzioni M., LeSage G.D., Glaser S., et al. Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats. American Journal of Physiology - Gastrointestinal and Liver Physiology 2003, 284:G837-G852.
54. Reinehr R., Häussinger D. Inhibition of bile salt-induced apoptosis by cyclic AMP involves serine/threonine phosphorylation of CD95. Gastroenterology 2004, 126:249-262.
55. Sommerfeld A., Reinehr R., Häussinger D. Bile acid-induced epidermal growth factor receptor activation in quiescent rat hepatic stellate cells can trigger both proliferation and apoptosis. Journal of Biological Chemistry 2009, 284:22173-22183.
56. Yasuda H., Hirata S., Inoue K., Mashima H., Ohnishi H., Yoshiba M. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochemical and Biophysical Research Communications 2007, 354:154-159.
57. Chen W.-D., Yu D., Forman B.M., Huang W., Wang Y.-D. The deficiency of G-protein-coupled bile acid receptor gpbar1 (TGR5) enhances chemically-induced liver carcinogenesis. Hepatology 2012.
58. He G., Yu G.-Y., Temkin V., et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cells 2010, 17:286-297.
59. Alemi F., Poole D.P., Chiu J., et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 2012.
60. - secretion via cAMP signaling and increases cystic fibrosis transmembrane conductance regulator phosphorylation in T84 cells. American Journal of Physiology - Cell Physiology 2013, 305:C447-C456.
61. Harach T., Pols T.W.H., Nomura M., et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Science Reporter 2012, 2:430.
62. Potthoff M.J., Potts A., He T., et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. American Journal of Physiology - Gastrointestinal and Liver Physiology 2013, 304:G371-G380. 10.1152/ajpgi.00400.2012.
63. Wu T., Bound M.J., Standfield S.D., et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes, Obesity and Metabolism 2013, 15:474-477.
64. Kida T., Tsubosaka Y., Hori M., et al. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2013, 33(7):1663-1669.
65. Hartman H.B., Gardell S.J., Petucci C.J., Wang S., Krueger J.A., Evans M.J. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. Journal of Lipid Research 2009, 50:1090-1100.
66. Mencarelli A., Cipriani S., Renga B., et al. The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. PLoS ONE 2010, 5:e13238.
67. Duboc H., Aelion H., Rainteau D., et al. Crosstalk between the hepatologist and the cardiologist: a future place for the lithocholic acid as a coronary atheroma risk factor?. Hepatology 2012, 56(6):2426.
68. McMahan R.H., Wang X.X., Cheng L.L., et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. Journal of Biological Chemistry 2013, 288:11761-11770.
69. Tzirogiannis K.N., Papadimas G.K., Kondyli V.G., et al. Peliosis hepatis: microscopic and macroscopic type, time pattern, and correlation with liver cell apoptosis in a model of toxic liver injury. Digestive Diseases and Sciences 2006, 51:1998-2006.
70. Hartleb M., Gutkowski K., Milkiewicz P. Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension. World Journal of Gastroenterology 2011, 17:1400-1409.
71. Reinehr R., Görg B., Becker S., et al. Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices. Glia 2007, 55:758-771.
72. Görg B., Qvartskhava N., Keitel V., et al. Ammonia induces RNA oxidation in cultured astrocytes and brain in vivo. Hepatology 2008, 48:567-579.
73. Perides G., Laukkarinen J.M., Vassileva G., Steer M.L. Biliary acute pancreatitis in mice is mediated by the G-protein-coupled cell surface bile acid receptor Gpbar1. Gastroenterology 2010, 138:715-725.
74. Karlsen T.H., Franke A., Melum E., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010, 138:1102-1111.
75. Loftus E.V., Harewood G.C., Loftus C.G., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
76. Yoneno K., Hisamatsu T., Shimamura K., et al. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. Immunology 2013, 139:19-29.
77. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. New England Journal of Medicine 2012, 367:1626-1635.
78. Manabe N., Wong B.S., Camilleri M., Burton D., McKinzie S., Zinsmeister A.R. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterology and Motility 2010, 22:293-382.
79. Sabate J.-M., Veyrac M., Mion F., et al. Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2008, 28:484-490.
80. Coffin B., Bouhassira D., Sabaté J.-M., Barbe L., Jian R. Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut 2004, 53:1465-1470.
81. Camilleri M., Vazquez-Roque M.I., Carlson P., Burton D., Wong B.S., Zinsmeister A.R. Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neurogastroenterology and Motility 2011, 23:995-999. e458.
82. Gerova V.A., Stoynov S.G., Katsarov D.S., Svinarov D.A. Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test. World Journal of Gastroenterology 2011, 17:2211-2215.
83. Bertiaux-Vandaële N., Youmba S.B., Belmonte L., et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. American Journal of Gastroenterology 2011, 106:2165-2173.
84. Ridlon J.M., Kang D.-J., Hylemon P.B. Bile salt biotransformations by human intestinal bacteria. Journal of Lipid Research 2006, 47:241-259.
85. Hill M.J. Bile acids and colorectal cancer: hypothesis. European Journal of Cancer Prevention 1991, 1(Suppl. 2):69-74.
86. Reddy B.S., Wynder E.L. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer 1977, 39:2533-2539.
87. Debruyne P.R., Bruyneel E.A., Li X., Zimber A., Gespach C., Mareel M.M. The role of bile acids in carcinogenesis. Mutation Research 2001, 480-481:359-369.
88. Bernstein C., Holubec H., Bhattacharyya A.K., et al. Carcinogenicity of deoxycholate, a secondary bile acid. Archives of Toxicology 2011, 85:863-871.
89. Kong Y., Bai P.S., Sun H., et al. The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer. International Journal of Biochemistry and Cell Biology 2012, 44(12):2321-2332.
90. Hong J., Behar J., Wands J., et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 2010, 59:170-180.
91. Lundegårdh G., Adami H.O., Helmick C., Zack M., Meirik O. Stomach cancer after partial gastrectomy for benign ulcer disease. New England Journal of Medicine 1988, 319:195-200.
92. Lundegårdh G., Adami H.O., Helmick C., Zack M. Risk of cancer following partial gastrectomy for benign ulcer disease. British Journal of Surgery 1994, 81:1164-1167.
93. Cao W., Tian W., Hong J., et al. Expression of bile acid receptor TGR5 in gastric adenocarcinoma. American Journal of Physiology - Gastrointestinal and Liver Physiology 2013, 304:G322-G327.